Biogen Announces $5.6 Billion Acquisition to Expand into Immunology and Nephrology

Biogen Inc. (BIIB) has officially identified Apellis Pharmaceuticals as the target of its $5.6 billion acquisition, a move aimed at strengthening its presence in immunology and rare diseases. The transaction includes the acquisition of two key drugs, EMPAVELI® and SYFOVRE®, which generated combined net sales of $689 million in 2025. As part of the deal structure, Biogen has included a contingent value right (CVR) tied to the future sales performance of SYFOVRE®. This strategic expansion allows Biogen to diversify its revenue streams beyond its core neurology business into the high-growth nephrology market. The acquisition is expected to be accretive to Biogen's non-GAAP earnings per share (EPS) starting in 2027. Analysts view this investment as a significant step toward long-term portfolio growth and enhanced shareholder value in the biotech sector.